1
|
Clement-Lacroix P, Little CB, Smith MM, Cottereaux C, Merciris D, Meurisse S, Mollat P, Touitou R, Brebion F, Gosmini R, De Ceuninck F, Botez I, Lepescheux L, van der Aar E, Christophe T, Vandervoort N, Blanqué R, Comas D, Deprez P, Amantini D. Pharmacological characterization of GLPG1972/S201086, a potent and selective small-molecule inhibitor of ADAMTS5. Osteoarthritis Cartilage 2022; 30:291-301. [PMID: 34626798 DOI: 10.1016/j.joca.2021.08.012] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2021] [Revised: 07/29/2021] [Accepted: 08/09/2021] [Indexed: 02/02/2023]
Abstract
OBJECTIVE A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) is a key enzyme in degradation of cartilage in osteoarthritis (OA). We report the pharmacological characterization of GLPG1972/S201086, a new, potent and selective small-molecule ADAMTS5 inhibitor. METHODS Potency and selectivity of GLPG1972/S201086 for ADAMTS5 were determined using fluorescently labeled peptide substrates. Inhibitory effects of GLPG1972/S201086 on interleukin-1α-stimulated glycosaminoglycan release in mouse femoral head cartilage explants and on interleukin-1β-stimulated release of an ADAMTS5-derived aggrecan neoepitope (quantified with ELISA) in human articular cartilage explants were determined. In the destabilization of the medial meniscus (DMM) mouse and menisectomized (MNX) rat models, effects of oral GLPG1972/S201086 on relevant OA histological and histomorphometric parameters were evaluated. RESULTS GLPG1972/S201086 inhibited human and rat ADAMTS5 (IC50 ± SD: 19 ± 2 nM and <23 ± 1 nM, respectively), with 8-fold selectivity over ADAMTS4, and 60->5,000-fold selectivity over other related proteases in humans. GLPG1972/S201086 dose-dependently inhibited cytokine-stimulated aggrenolysis in mouse and human cartilage explants (100% at 20 μM and 10 μM, respectively). In DMM mice, GLPG1972/S201086 (30-120 mg/kg b.i.d) vs vehicle reduced femorotibial cartilage proteoglycan loss (23-37%), cartilage structural damage (23-39%) and subchondral bone sclerosis (21-36%). In MNX rats, GLPG1972/S201086 (10-50 mg/kg b.i.d) vs vehicle reduced cartilage damage (OARSI score reduction, 6-23%), and decreased proteoglycan loss (∼27%) and subchondral bone sclerosis (77-110%). CONCLUSIONS GLPG1972/S201086 is a potent, selective and orally available ADAMTS5 inhibitor, demonstrating significant protective efficacy on both cartilage and subchondral bone in two relevant in vivo preclinical OA models.
Collapse
Affiliation(s)
| | - C B Little
- Raymond Purves Bone and Joint Research Laboratories, University of Sydney, Kolling Institute, Northern Sydney Local Health District, Royal North Shore Hospital, St Leonards, NSW, Australia.
| | - M M Smith
- Raymond Purves Bone and Joint Research Laboratories, University of Sydney, Kolling Institute, Northern Sydney Local Health District, Royal North Shore Hospital, St Leonards, NSW, Australia.
| | | | | | | | - P Mollat
- Galapagos SASU, Romainville, France.
| | - R Touitou
- Galapagos SASU, Romainville, France.
| | - F Brebion
- Galapagos SASU, Romainville, France.
| | - R Gosmini
- Galapagos SASU, Romainville, France.
| | | | - I Botez
- Institut de Recherches Servier, France.
| | | | | | | | | | - R Blanqué
- Galapagos SASU, Romainville, France.
| | - D Comas
- Galapagos SASU, Romainville, France.
| | - P Deprez
- Galapagos SASU, Romainville, France.
| | | |
Collapse
|
2
|
Pluda S, Mazzocato Y, Angelini A. Peptide-Based Inhibitors of ADAM and ADAMTS Metalloproteinases. Front Mol Biosci 2021; 8:703715. [PMID: 34368231 PMCID: PMC8335159 DOI: 10.3389/fmolb.2021.703715] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Accepted: 06/30/2021] [Indexed: 12/30/2022] Open
Abstract
ADAM and ADAMTS are two large metalloproteinase families involved in numerous physiological processes, such as shedding of cell-surface protein ectodomains and extra-cellular matrix remodelling. Aberrant expression or dysregulation of ADAMs and ADAMTSs activity has been linked to several pathologies including cancer, inflammatory, neurodegenerative and cardiovascular diseases. Inhibition of ADAM and ADAMTS metalloproteinases have been attempted using various small molecules and protein-based therapeutics, each with their advantages and disadvantages. While most of these molecular formats have already been described in detail elsewhere, this mini review focuses solely on peptide-based inhibitors, an emerging class of therapeutic molecules recently applied against some ADAM and ADAMTS members. We describe both linear and cyclic peptide-based inhibitors which have been developed using different approaches ranging from traditional medicinal chemistry and rational design strategies to novel combinatorial peptide-display technologies.
Collapse
Affiliation(s)
- Stefano Pluda
- Department of Molecular Sciences and Nanosystems, Ca’ Foscari University of Venice, Venice, Italy
- Fidia Farmaceutici S.p.A., Abano Terme, Italy
| | - Ylenia Mazzocato
- Department of Molecular Sciences and Nanosystems, Ca’ Foscari University of Venice, Venice, Italy
| | - Alessandro Angelini
- Department of Molecular Sciences and Nanosystems, Ca’ Foscari University of Venice, Venice, Italy
- European Centre for Living Technology (ECLT), Venice, Italy
| |
Collapse
|
3
|
Bellini M, Pest MA, Miranda-Rodrigues M, Qin L, Jeong JW, Beier F. Overexpression of MIG-6 in the cartilage induces an osteoarthritis-like phenotype in mice. Arthritis Res Ther 2020; 22:119. [PMID: 32430054 PMCID: PMC7236969 DOI: 10.1186/s13075-020-02213-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Accepted: 05/06/2020] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Osteoarthritis (OA) is the most common form of arthritis and characterized by degeneration of the articular cartilage. Mitogen-inducible gene 6 (Mig-6) has been identified as a negative regulator of the epidermal growth factor receptor (EGFR). Cartilage-specific Mig-6 knockout (KO) mice display increased EGFR signaling, an anabolic buildup of the articular cartilage, and formation of chondro-osseous nodules. Since our understanding of the EGFR/Mig-6 network in the cartilage remains incomplete, we characterized mice with cartilage-specific overexpression of Mig-6 in this study. METHODS Utilizing knee joints from cartilage-specific Mig-6-overexpressing (Mig-6over/over) mice (at multiple time points), we evaluated the articular cartilage using histology, immunohistochemical staining, and semi-quantitative histopathological scoring (OARSI) at multiple ages. MicroCT analysis was employed to examine skeletal morphometry, body composition, and bone mineral density. RESULTS Our data show that cartilage-specific Mig-6 overexpression did not cause any major developmental abnormalities in the articular cartilage, although Mig-6over/over mice have slightly shorter long bones compared to the control group. Moreover, there was no significant difference in bone mineral density and body composition in any of the groups. However, our results indicate that Mig-6over/over male mice show accelerated cartilage degeneration at 12 and 18 months of age. Immunohistochemistry for SOX9 demonstrated that the number of positively stained cells in Mig-6over/over mice was decreased relative to controls. Immunostaining for MMP13 appeared increased in areas of cartilage degeneration in Mig-6over/over mice. Moreover, staining for phospho-EGFR (Tyr-1173) and lubricin (PRG4) was decreased in the articular cartilage of Mig-6over/over mice. CONCLUSION Overexpression of Mig-6 in the articular cartilage causes no major developmental phenotype; however, these mice develop earlier OA during aging. These data demonstrate that Mig-6/EGFR pathways are critical for joint homeostasis and might present a promising therapeutic target for OA.
Collapse
Affiliation(s)
- Melina Bellini
- Department of Physiology and Pharmacology, Western University, London, ON, Canada
- Western University Bone and Joint Institute, London, ON, Canada
| | - Michael A Pest
- Department of Physiology and Pharmacology, Western University, London, ON, Canada
- Western University Bone and Joint Institute, London, ON, Canada
| | - Manuela Miranda-Rodrigues
- Department of Physiology and Pharmacology, Western University, London, ON, Canada
- Western University Bone and Joint Institute, London, ON, Canada
- Children's Health Research Institute, London, ON, Canada
| | - Ling Qin
- Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Jae-Wook Jeong
- Department of Obstetrics, Gynecology and Reproductive Biology, Michigan State University College of Human Medicine, Grand Rapids, MI, USA
| | - Frank Beier
- Department of Physiology and Pharmacology, Western University, London, ON, Canada.
- Western University Bone and Joint Institute, London, ON, Canada.
- Children's Health Research Institute, London, ON, Canada.
| |
Collapse
|
4
|
Özer D, Eyigör S. Osteoartrozda yeni tedavi yöntemleri. EGE TIP DERGISI 2019. [DOI: 10.19161/etd.648590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
5
|
Miller RE, Ishihara S, Tran PB, Golub SB, Last K, Miller RJ, Fosang AJ, Malfait AM. An aggrecan fragment drives osteoarthritis pain through Toll-like receptor 2. JCI Insight 2018; 3:95704. [PMID: 29563338 DOI: 10.1172/jci.insight.95704] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Accepted: 02/20/2018] [Indexed: 01/22/2023] Open
Abstract
Pain is the predominant symptom of osteoarthritis, but the connection between joint damage and the genesis of pain is not well understood. Loss of articular cartilage is a hallmark of osteoarthritis, and it occurs through enzymatic degradation of aggrecan by cleavage mediated by a disintegrin and metalloproteinase with thrombospondin motif 4 (ADAMTS-4) or ADAMTS-5 in the interglobular domain (E373-374A). Further cleavage by MMPs (N341-342F) releases a 32-amino-acid aggrecan fragment (32-mer). We investigated the role of this 32-mer in driving joint pain. We found that the 32-mer excites dorsal root ganglion nociceptive neurons, both in culture and in intact explants. Treatment of cultured sensory neurons with the 32-mer induced expression of the proalgesic chemokine CCL2. These effects were mediated through TLR2, which we demonstrated was expressed by nociceptive neurons. In addition, intra-articular injection of the 32-mer fragment provoked knee hyperalgesia in WT but not Tlr2-null mice. Blocking the production or action of the 32-mer in transgenic mice prevented the development of knee hyperalgesia in a murine model of osteoarthritis. These findings suggest that the aggrecan 32-mer fragment directly activates TLR2 on joint nociceptors and is an important mediator of the development of osteoarthritis-associated joint pain.
Collapse
Affiliation(s)
- Rachel E Miller
- Department of Internal Medicine, Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA
| | - Shingo Ishihara
- Department of Internal Medicine, Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA
| | - Phuong B Tran
- Department of Internal Medicine, Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA
| | - Suzanne B Golub
- University of Melbourne Department of Paediatrics, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia
| | - Karena Last
- University of Melbourne Department of Paediatrics, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia
| | - Richard J Miller
- Department of Pharmacology, Northwestern University, Chicago, Illinois, USA
| | - Amanda J Fosang
- University of Melbourne Department of Paediatrics, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia
| | - Anne-Marie Malfait
- Department of Internal Medicine, Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA
| |
Collapse
|
6
|
Durham TB, Marimuthu J, Toth JL, Liu C, Adams L, Mudra DR, Swearingen C, Lin C, Chambers MG, Thirunavukkarasu K, Wiley MR. A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose. J Med Chem 2017; 60:5933-5939. [PMID: 28613895 DOI: 10.1021/acs.jmedchem.7b00650] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Aggrecanase-1 and -2 (ADAMTS-4 and ADAMTS-5) are zinc metalloproteases involved in the degradation of aggrecan in cartilage. Inhibitors could provide a means of altering the progression of osteoarthritis. We report the identification of 7 which had good oral pharmacokinetics in rats and showed efficacy in a rat chemical model of osteoarthritis. The projected human dose required to achieve sustained plasma levels ≥10 times the hADAMTS-5 IC50 is 5 mg q.d.
Collapse
Affiliation(s)
- Timothy B Durham
- Eli Lilly and Company , Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Jothirajah Marimuthu
- Eli Lilly and Company , Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - James L Toth
- Eli Lilly and Company , Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Chin Liu
- Eli Lilly and Company , Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Lisa Adams
- Eli Lilly and Company , Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Daniel R Mudra
- Eli Lilly and Company , Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Craig Swearingen
- Eli Lilly and Company , Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Chaohua Lin
- Eli Lilly and Company , Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Mark G Chambers
- Eli Lilly and Company , Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | | | - Michael R Wiley
- Eli Lilly and Company , Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| |
Collapse
|
7
|
Prudnikova K, Yucha RW, Patel P, Kriete AS, Han L, Penn LS, Marcolongo MS. Biomimetic Proteoglycans Mimic Macromolecular Architecture and Water Uptake of Natural Proteoglycans. Biomacromolecules 2017; 18:1713-1723. [DOI: 10.1021/acs.biomac.7b00032] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- Katsiaryna Prudnikova
- Department of Materials Science
and Engineering, ‡School of Biomedical Engineering, Science and Health Systems, and ∥Department of
Chemistry, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, United States
| | - Robert W. Yucha
- Department of Materials Science
and Engineering, ‡School of Biomedical Engineering, Science and Health Systems, and ∥Department of
Chemistry, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, United States
| | - Pavan Patel
- Department of Materials Science
and Engineering, ‡School of Biomedical Engineering, Science and Health Systems, and ∥Department of
Chemistry, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, United States
| | - Alicia S. Kriete
- Department of Materials Science
and Engineering, ‡School of Biomedical Engineering, Science and Health Systems, and ∥Department of
Chemistry, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, United States
| | - Lin Han
- Department of Materials Science
and Engineering, ‡School of Biomedical Engineering, Science and Health Systems, and ∥Department of
Chemistry, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, United States
| | - Lynn S. Penn
- Department of Materials Science
and Engineering, ‡School of Biomedical Engineering, Science and Health Systems, and ∥Department of
Chemistry, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, United States
| | - Michele S. Marcolongo
- Department of Materials Science
and Engineering, ‡School of Biomedical Engineering, Science and Health Systems, and ∥Department of
Chemistry, Drexel University, 3141 Chestnut Street, Philadelphia, Pennsylvania 19104, United States
| |
Collapse
|
8
|
Watt FE, Gulati M. New Drug Treatments for Osteoarthritis: What Is on the Horizon? EUROPEAN MEDICAL JOURNAL 2017. [DOI: 10.33590/emj/10314447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Osteoarthritis (OA) is the most common form of arthritis, yet has historically lagged far behind rheumatoid arthritis in terms of drug development. Despite the many challenges presented by clinical trials in OA, improvements in our understanding of disease pathogenesis and a move to treat pain, as well as underlying disease process, mean there are now many new pharmacological therapies currently in various stages of clinical trials. The medical need for these therapies and the evidence for recent tissue and molecular targets are reviewed. Current therapeutic examples in each area are discussed, including both novel therapeutics and existing agents which may be repurposed from other disease areas. Some challenges remain, but opportunities for improving symptoms and disease process in OA in the clinic with new pharmacological agents would appear to be on the close horizon.
Collapse
Affiliation(s)
- Fiona E. Watt
- Arthritis Research UK Centre for Osteoarthritis Pathogenesis, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
| | - Malvika Gulati
- Department of Rheumatology, Royal Free Hospital, London, UK
| |
Collapse
|
9
|
Inhibition of aggrecanases as a therapeutic strategy in osteoarthritis. Future Med Chem 2015; 6:1399-412. [PMID: 25329196 DOI: 10.4155/fmc.14.84] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Over the last decade, there has been a large effort to target aggrecanases, which are responsible for the degradation of the aggrecan in the extracellular matrix of joints, in order to hopefully lead to new treatments for osteoarthritis. Only a few inhibitors have been effective in explants or rodent models and thus only a few have reached the clinic, none of which have proven to be effective. In this article, a survey of chemical series is described, covering historical and recent inhibitors and highlighting how some of their problems were resolved, with a critical overview of the challenges encountered. A large effort should be undertaken in designing smaller compounds with higher residence times, defining new interaction sites on the aggrecanases and exploiting target flexibility.
Collapse
|
10
|
Ding Y, O’Keefe H, DeLorey JL, Israel DI, Messer JA, Chiu CH, Skinner SR, Matico RE, Murray-Thompson MF, Li F, Clark MA, Cuozzo JW, Arico-Muendel C, Morgan BA. Discovery of Potent and Selective Inhibitors for ADAMTS-4 through DNA-Encoded Library Technology (ELT). ACS Med Chem Lett 2015; 6:888-93. [PMID: 26288689 DOI: 10.1021/acsmedchemlett.5b00138] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2015] [Accepted: 07/07/2015] [Indexed: 12/12/2022] Open
Abstract
The aggrecan degrading metalloprotease ADAMTS-4 has been identified as a novel therapeutic target for osteoarthritis. Here, we use DNA-encoded Library Technology (ELT) to identify novel ADAMTS-4 inhibitors from a DNA-encoded triazine library by affinity selection. Structure-activity relationship studies based on the selection information led to the identification of potent and highly selective inhibitors. For example, 4-(((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-6-(((4-methylpiperazin-1-yl)methyl)amino)-1,3,5-triazin-2-yl)amino)methyl)-N-ethyl-N-(m-tolyl)benzamide has IC50 of 10 nM against ADAMTS-4, with >1000-fold selectivity over ADAMT-5, MMP-13, TACE, and ADAMTS-13. These inhibitors have no obvious zinc ligand functionality.
Collapse
Affiliation(s)
- Yun Ding
- Platform Technology & Science, GlaxoSmithKline, ELT-Boston, 830 Winter Street, Waltham, Massachusetts 02451, United States
| | - Heather O’Keefe
- Platform Technology & Science, GlaxoSmithKline, ELT-Boston, 830 Winter Street, Waltham, Massachusetts 02451, United States
| | - Jennifer L. DeLorey
- Tedor Pharma, Inc., 400 Highland Corporate Drive, Cumberland, Rhode Island 02864, United States
| | - David I. Israel
- Platform Technology & Science, GlaxoSmithKline, ELT-Boston, 830 Winter Street, Waltham, Massachusetts 02451, United States
| | - Jeffrey A. Messer
- Platform Technology & Science, GlaxoSmithKline, ELT-Boston, 830 Winter Street, Waltham, Massachusetts 02451, United States
| | - Cynthia H. Chiu
- Platform Technology & Science, GlaxoSmithKline, ELT-Boston, 830 Winter Street, Waltham, Massachusetts 02451, United States
| | - Steven R. Skinner
- Platform Technology & Science, GlaxoSmithKline, ELT-Boston, 830 Winter Street, Waltham, Massachusetts 02451, United States
| | - Rosalie E. Matico
- Biological
Reagent and Assay Development, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Monique F. Murray-Thompson
- Biological
Reagent and Assay Development, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, United States
| | - Fan Li
- Tufts Healthcare Institute, 136 Harrison Avenue, Boston, Massachusetts 02111, United States
| | - Matthew A. Clark
- X-Chem, Inc., 100 Beaver Street, Waltham, Massachusetts 02453, United States
| | - John W. Cuozzo
- X-Chem, Inc., 100 Beaver Street, Waltham, Massachusetts 02453, United States
| | - Christopher Arico-Muendel
- Platform Technology & Science, GlaxoSmithKline, ELT-Boston, 830 Winter Street, Waltham, Massachusetts 02451, United States
| | - Barry A. Morgan
- Center for Drug Discovery, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, United States
| |
Collapse
|
11
|
Larkin J, Lohr TA, Elefante L, Shearin J, Matico R, Su JL, Xue Y, Liu F, Genell C, Miller RE, Tran PB, Malfait AM, Maier CC, Matheny CJ. Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. Osteoarthritis Cartilage 2015; 23:1254-66. [PMID: 25800415 PMCID: PMC4516626 DOI: 10.1016/j.joca.2015.02.778] [Citation(s) in RCA: 91] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/29/2014] [Revised: 02/03/2015] [Accepted: 02/24/2015] [Indexed: 02/02/2023]
Abstract
OBJECTIVE/METHOD Aggrecanase activity, most notably ADAMTS-5, is implicated in pathogenic cartilage degradation. Selective monoclonal antibodies (mAbs) to both ADAMTS-5 and ADAMTS-4 were generated and in vitro, ex vivo and in vivo systems were utilized to assess target engagement, aggrecanase inhibition and modulation of disease-related endpoints with the intent of selecting a candidate for clinical development in osteoarthritis (OA). RESULTS Structural mapping predicts the most potent mAbs employ a unique mode of inhibition by cross-linking the catalytic and disintegrin domains. In a surgical mouse model of OA, both ADAMTS-5 and ADAMTS-4-specific mAbs penetrate cartilage following systemic administration, demonstrating access to the anticipated site of action. Structural disease modification and associated alleviation of pain-related behavior were observed with ADAMTS-5 mAb treatment. Treatment of human OA cartilage demonstrated a preferential role for ADAMTS-5 inhibition over ADAMTS-4, as measured by ARGS neoepitope release in explant cultures. ADAMTS-5 mAb activity was most evident in a subset of patient-derived tissues and suppression of ARGS neoepitope release was sustained for weeks after a single treatment in human explants and in cynomolgus monkeys, consistent with high affinity target engagement and slow ADAMTS-5 turnover. CONCLUSION This data supports a hypothesis set forth from knockout mouse studies that ADAMTS-5 is the major aggrecanase involved in cartilage degradation and provides a link between a biological pathway and pharmacology which translates to human tissues, non-human primate models and points to a target OA patient population. Therefore, a humanized ADAMTS-5-selective monoclonal antibody (GSK2394002) was progressed as a potential OA disease modifying therapeutic.
Collapse
Affiliation(s)
- Jonathan Larkin
- Experimental Medicine Unit – Immuno-Inflammation Therapeutic Area Unit, GlaxoSmithKline, Upper Merion, Pennsylvania, USA,Novel Targets Biopharm Discovery Unit – Biopharm R&D, GlaxoSmithKline, Upper Merion, Pennsylvania, USA,Corresponding author:
| | - Thomas A. Lohr
- Experimental Medicine Unit – Immuno-Inflammation Therapeutic Area Unit, GlaxoSmithKline, Upper Merion, Pennsylvania, USA,Novel Targets Biopharm Discovery Unit – Biopharm R&D, GlaxoSmithKline, Upper Merion, Pennsylvania, USA
| | - Louis Elefante
- Novel Targets Biopharm Discovery Unit – Biopharm R&D, GlaxoSmithKline, Upper Merion, Pennsylvania, USA
| | - Jean Shearin
- Biological Sciences, GlaxoSmithKline, Upper Merion, Pennsylvania, USA
| | - Rosalie Matico
- Biological Sciences, GlaxoSmithKline, Upper Merion, Pennsylvania, USA
| | - Jui-Lan Su
- Biological Sciences, GlaxoSmithKline, Upper Merion, Pennsylvania, USA
| | - Yu Xue
- Novel Targets Biopharm Discovery Unit – Biopharm R&D, GlaxoSmithKline, Upper Merion, Pennsylvania, USA
| | - Feng Liu
- Quantitative Sciences, GlaxoSmithKline, Upper Merion, Pennsylvania, USA
| | - Caroline Genell
- ImmunoToxicology – Platform Technology & Science, GlaxoSmithKline, Upper Merion, Pennsylvania, USA
| | - Rachel E. Miller
- Department of Internal Medicine (Rheumatology), Rush University Medical Center; Chicago, Illinois
| | - Phuong B. Tran
- Department of Internal Medicine (Rheumatology), Rush University Medical Center; Chicago, Illinois
| | - Anne-Marie Malfait
- Department of Internal Medicine (Rheumatology), Rush University Medical Center; Chicago, Illinois
| | - Curtis C. Maier
- ImmunoToxicology – Platform Technology & Science, GlaxoSmithKline, Upper Merion, Pennsylvania, USA
| | | |
Collapse
|
12
|
Durham TB, Klimkowski VJ, Rito CJ, Marimuthu J, Toth JL, Liu C, Durbin JD, Stout SL, Adams L, Swearingen C, Lin C, Chambers MG, Thirunavukkarasu K, Wiley MR. Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis. J Med Chem 2014; 57:10476-85. [PMID: 25415648 DOI: 10.1021/jm501522n] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
A disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4) and ADAMTS-5 are zinc metalloproteases commonly referred to as aggrecanase-1 and aggrecanase-2, respectively. These enzymes are involved in the degradation of aggrecan, a key component of cartilage. Inhibitors of these enzymes could be potential osteoarthritis (OA) therapies. A series of hydantoin inhibitors of ADAMTS-4 and ADAMTS-5 were identified from a screening campaign and optimized through structure-based drug design to give hydantoin 13. Hydantoin 13 had excellent selectivity over other zinc metalloproteases such as TACE, MMP2, MMP3, MMP13, and MMP14. The compound also produced efficacy in both a chemically induced and surgical model of OA in rats.
Collapse
Affiliation(s)
- Timothy B Durham
- Eli Lilly and Company, Lilly Corporate Center , Indianapolis, Indiana 46285, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Deng H, O'Keefe H, Davie CP, Lind KE, Acharya RA, Franklin GJ, Larkin J, Matico R, Neeb M, Thompson MM, Lohr T, Gross JW, Centrella PA, O'Donovan GK, Bedard KLS, van Vloten K, Mataruse S, Skinner SR, Belyanskaya SL, Carpenter TY, Shearer TW, Clark MA, Cuozzo JW, Arico-Muendel CC, Morgan BA. Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology (ELT). J Med Chem 2012; 55:7061-79. [PMID: 22891645 DOI: 10.1021/jm300449x] [Citation(s) in RCA: 110] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The metalloprotease ADAMTS-5 is considered a potential target for the treatment of osteoarthritis. To identify selective inhibitors of ADAMTS-5, we employed encoded library technology (ELT), which enables affinity selection of small molecule binders from complex mixtures by DNA tagging. Selection of ADAMTS-5 against a four-billion member ELT library led to a novel inhibitor scaffold not containing a classical zinc-binding functionality. One exemplar, (R)-N-((1-(4-(but-3-en-1-ylamino)-6-(((2-(thiophen-2-yl)thiazol-4-yl)methyl)amino)-1,3,5-triazin-2-yl)pyrrolidin-2-yl)methyl)-4-propylbenzenesulfonamide (8), inhibited ADAMTS-5 with IC(50) = 30 nM, showing >50-fold selectivity against ADAMTS-4 and >1000-fold selectivity against ADAMTS-1, ADAMTS-13, MMP-13, and TACE. Extensive SAR studies showed that potency and physicochemical properties of the scaffold could be further improved. Furthermore, in a human osteoarthritis cartilage explant study, compounds 8 and 15f inhibited aggrecanase-mediated (374)ARGS neoepitope release from aggrecan and glycosaminoglycan in response to IL-1β/OSM stimulation. This study provides the first small molecule evidence for the critical role of ADAMTS-5 in human cartilage degradation.
Collapse
Affiliation(s)
- Hongfeng Deng
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Martel-Pelletier J, Wildi LM, Pelletier JP. Future therapeutics for osteoarthritis. Bone 2012; 51:297-311. [PMID: 22037003 DOI: 10.1016/j.bone.2011.10.008] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2011] [Accepted: 10/07/2011] [Indexed: 11/26/2022]
Abstract
Osteoarthritis (OA) is a disease of the joints that affects several million individuals worldwide. This disease, which involves mainly the diarthrodial joints, is chronic and develops slowly over decades, making it very difficult to precisely identify the different etiological and risk factors that influence its onset. At present, most therapies for OA are symptomatic. This review will focus on new OA therapeutics in development that are directed toward pain relief as well as others with the potential to reduce or stop the progression of the disease (DMOADs). This article is part of a Special Issue entitled "Osteoarthritis".
Collapse
Affiliation(s)
- Johanne Martel-Pelletier
- Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada.
| | | | | |
Collapse
|
15
|
Morawski M, Brückner G, Arendt T, Matthews R. Aggrecan: Beyond cartilage and into the brain. Int J Biochem Cell Biol 2012; 44:690-3. [DOI: 10.1016/j.biocel.2012.01.010] [Citation(s) in RCA: 85] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2011] [Revised: 01/14/2012] [Accepted: 01/17/2012] [Indexed: 12/18/2022]
|
16
|
Bondeson J. Are we moving in the right direction with osteoarthritis drug discovery? Expert Opin Ther Targets 2011; 15:1355-68. [PMID: 22087738 DOI: 10.1517/14728222.2011.636740] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION The success of targeted biologic therapy against rheumatoid arthritis has meant that much research has been devoted to investigating the pathophysiology of osteoarthritis, in the hope of defining novel therapeutic targets. Osteoarthritis has long been thought of mainly as a degenerative disease of cartilage, with secondary bony damage and osteophytes. However, in recent years, the importance of the synovium, and in particular the synovial macrophages, has been highlighted in both in vitro and in vivo studies. AREAS COVERED The recent progress in osteoarthritis drug discovery, particularly with regard to the search for therapeutic targets for this disease and the development of disease-modifying anti-osteoarthritic drugs is critically assessed. Some important recent research with regard to possible therapeutic targets in osteoarthritis drug discovery is highlighted. EXPERT OPINION The concept that synovial macrophages and macrophage-produced cytokines, may play a role in driving inflammatory and destructive signalling pathways in osteoarthritis, is of importance for drug discovery in this disease, in spite of disappointing results from early studies of anti-cytokine strategies in osteoarthritis clinical trials. There is also an abundance of potential downstream therapeutic targets in osteoarthritis, including the matrix metalloproteinases, the aggrecanases, iNOS and elements of the Wnt pathway.
Collapse
Affiliation(s)
- Jan Bondeson
- Cardiff University, Department of Rheumatology, Heath Park, Cardiff CF14 4XN, UK.
| |
Collapse
|
17
|
Acikalin S, Raabe G, Runsink J, Gais HJ. Asymmetric Synthesis of Functionalized Bicyclic β-Amino Alcohols by Cascade Hydrometallation-Cyclization-Reduction of Glycinyl-Substituted Alkenylsulfoximines - Application to the Synthesis of an Aggrecanase Inhibitor Mimic. European J Org Chem 2011. [DOI: 10.1002/ejoc.201100868] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
18
|
Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis. Bioorg Med Chem Lett 2011; 21:3301-6. [DOI: 10.1016/j.bmcl.2011.04.028] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2011] [Revised: 04/02/2011] [Accepted: 04/06/2011] [Indexed: 11/24/2022]
|
19
|
The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis. Bioorg Med Chem Lett 2011; 21:1376-81. [PMID: 21300546 DOI: 10.1016/j.bmcl.2011.01.036] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2010] [Revised: 01/08/2011] [Accepted: 01/10/2011] [Indexed: 12/11/2022]
Abstract
Two series of N-hydroxyformamide inhibitors of ADAM-TS4 were identified from screening compounds previously synthesised as inhibitors of matrix metalloproteinase-13 (collagenase-3). Understanding of the binding mode of this class of compound using ADAM-TS1 as a structural surrogate has led to the discovery of potent and very selective inhibitors with favourable DMPK properties. Synthesis, structure-activity relationships, and strategies to improve selectivity and lower in vivo metabolic clearance are described.
Collapse
|